Explore the words cloud of the ESCALON project. It provides you a very rough idea of what is the project "ESCALON" about.
The following table provides information about the project.
Coordinator |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address contact info |
Coordinator Country | Netherlands [NL] |
Total cost | 3˙503˙475 € |
EC max contribution | 3˙283˙475 € (94%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SC1-2018-Single-Stage-RTD |
Funding Scheme | RIA |
Starting year | 2019 |
Duration (year-month-day) | from 2019-01-01 to 2022-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | NL (ROTTERDAM) | coordinator | 1˙386˙725.00 |
2 | ASOCIACION INSTITUTO BIODONOSTIA | ES (DONOSTIA-SAN SEBASTIAN) | participant | 550˙000.00 |
3 | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE | CL (SANTIAGO) | participant | 430˙000.00 |
4 | HOSPIAL PRIVADO CENTRO MEDICO DE CORDOBA SA | AR (CORDOBA) | participant | 301˙250.00 |
5 | UNIVERSIDAD SAN FRANCISCO DE QUITO | EC (QUITO) | participant | 172˙750.00 |
6 | MEDIZINISCHE HOCHSCHULE HANNOVER | DE (HANNOVER) | participant | 145˙000.00 |
7 | CENTRO DE ENFERMEDADES HEPATICAS Y DIGESTIVAS SAS | CO (BOGOTA) | participant | 117˙750.00 |
8 | SENSU HOLDING BV | NL (GRONINGEN) | participant | 95˙000.00 |
9 | THE UNIVERSITY OF MANCHESTER | UK (MANCHESTER) | participant | 85˙000.00 |
10 | FUNDACAO UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE | BR (PORTO ALEGRE) | participant | 0.00 |
11 | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO | CA (TORONTO) | participant | 0.00 |
Hepatobiliary malignancies represent a major cause of mortality globally and are uniquely aggressive in Latin America. The most common tumors are: hepatocellular carcinoma (HCC) affecting young individuals in Latin America and being the second most common cause of cancer-related death worldwide; cholangiocarcinoma (CCA) with minimal survival upon diagnosis and largely understudied in the region; gallbladder cancer (GBC) being a rare tumor worldwide but representing the second most common cause of cancer-related death in women in Chile. Key factors related to the excessive mortality of these tumors are the lack of reliable screening methods and the complexity of diagnosis, which requires advanced imaging technology and difficult-to-access tissue. These barriers are amplified by poor accessibility present in resource-limited regions, all of which leads to tumors being diagnosed at advanced stages in which curative therapy is not an option. To overcome these barriers, we propose to: A) validate immune-related markers in serum to predict HCC in South America and evaluate factors associated to early HCC development; B) define the utility of extracellular vesicles in serum as biomarkers for diagnosis of CCA and determine genetic and infectious factors that increase risk for this cancer; and C) identify biomarkers for GBC detection and evaluate novel immune factors that affect the geographical impact of this tumor. This project advances the field by focusing on a unique approach to screen and diagnose tumors based on serum detection of biomarkers before a tumor is visible on imaging, allowing for early tumor detection in a cost effective manner that will lead to implementation of curative therapies. In addition, this project addresses modifiable risk factors for hepatobiliary tumors that could be targeted for prevention. This project will result in novel tools that are easily accessible and will dramatically reduce the burden of cancer-related mortality in Latin America.
year | authors and title | journal | last update |
---|---|---|---|
2019 |
Jesus M. Banales, Mercedes Iñarrairaegui, Ander Arbelaiz, Piotr Milkiewicz, Jordi Muntané, Luis Muñoz-Bellvis, Adelaida La Casta, Luis M. Gonzalez, Enara Arretxe, Cristina Alonso, Ibon MartÃnez-Arranz, Ainhoa Lapitz, Alvaro Santos-Laso, Matias A. Avila, Maria L. MartÃnez-Chantar, Luis Bujanda, Jose J.G. Marin, Bruno Sangro, Rocio I.R. Macias Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis published pages: 547-562, ISSN: 0270-9139, DOI: 10.1002/hep.30319 |
Hepatology 70/2 | 2020-04-21 |
2019 |
Jose D Debes, Andre Boonstra, Domingo Balderramo, Angelo Z Mattos, Marco Arrese, Juan C. Roa, Juan W. Valle, Jesus M. Banales, Enrique Carrera, Pablo A. Romagnoli, Jhon E. Prieto, Bettina E. Hansen, Arndt Vogel, Angela Lamarca Hepatobiliary cancers in South America: disparity strikes published pages: 581, ISSN: 2468-1253, DOI: 10.1016/s2468-1253(19)30188-8 |
The Lancet Gastroenterology & Hepatology 4/8 | 2020-04-21 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESCALON" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ESCALON" are provided by the European Opendata Portal: CORDIS opendata.